Medicamen Organics Ltd

Medicamen Organics Ltd IPO

IPO Price Range: ₹32 - 34

Medicamen Organics Limited is engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government (including both state and central governments) and private institutions as contract manufacturer / third party manufacturer. The Company markets its product to private pharma companies in domestic as well as international markets through third party distributors or on loan license basis. Further, the Company is also strategically focusing on establishing a direct presence in international market for an instance in fiscal 2023, it has directly exported its product in Burundi. The Company has a track record of operating B2B model which covers contract manufacturing model. Its products are marketed across India as well as African, Commonwealth of Independent States (CIS) region and south East Asian Countries like Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya by its third-party distributor.

Min Investment

₹1,36,000

IPO Size

₹10 Cr

IPO Status

Closed

Quantity in 1 Lot

4000

Max Bid allowed

1

Listing Exchange

NSE

IPO Application Timeline of Medicamen Organics Ltd

Open Date21 Jun 2024
Close Date25 Jun 2024
Allotment Date26 Jun 2024
Listing Date28 Jun 2024

Key Statistics

Bid Opening DateBid Opening Date21 Jun 2024
Bid Closing DateBid Closing Date25 Jun 2024
Allotment DateAllotment Date26 Jun 2024
Issue SizeIssue Size₹10.54Cr
Quantity in 1 lotQuantity in 1 lot4000

Strength and risks

Strength

Strength

  • Experienced Promoters and Management Team.

  • Long standing relationships with customers.

  • Efficient operational team.

  • Consistent financial performance.


Risk

Risk

  • The Company, its Directors and its Promoters are party to certain litigation and claims. These legal proceedings are pending at different levels of adjudication before various forums and regulatory authorities. Any adverse decision may make it liable to liabilities/penalties and may adversely affect its reputation, business and financial status.

  • The company requires a number of approvals, licenses, registrations and permits in the ordinary course of its business and any failures or delay in obtaining the same in a timely manner may adversely affect its operations.

  • Its business activities are exposed to fluctuations in the prices of raw materials.

  • The Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect its revenues and profitability.

  • The Company is dependent on few suppliers for purchase of product. Loss of any of these large suppliers may affect its business operations.

  • The restated examination report by its peer review auditor on Restated Financial Statements has provided a matter of emphasis paragraph for the company has not accounted for interest provisions as per MSMED Act, 2006.

  • Its Registered Office and the company factories are located on premises which are not owned by it and has been obtained on lease basis. Disruption of its rights as licensee/ lessee or termination of the agreements with its licensors/ lessors would adversely impact the company operations and, consequently, its business, financial condition and results of operations.

  • The Company has entered into certain related party transactions and may continue to do so in the future.

  • Its may be unable to sufficiently obtain, maintain, protect, or enforce the company intellectual property and other proprietary rights.

  • Some of its corporate records relating to changes in the share capital of the Company, allotments made by the Company, and transfers and acquisitions of Equity Shares made by its Promoters, not traceable. There have been instances of non-filing of certain ROC forms which were required to be filed as per the reporting requirements under the Companies Act, 2013 to RoC.

Promoters Holding

Investors Holdings %
Bal Kishan Gupta70.96%
Ashutosh Gupta6.83%

About Medicamen Organics Ltd

OrganisationMedicamen Organics Ltd
HeadquartersNew Delhi
IndustryPharmaceuticals

Frequently Asked Questions

  • What is the size of the Medicamen Organics Ltd IPO?

    The size of the Medicamen Organics Ltd IPO is ₹10.54Cr .

  • What is 'pre-apply' for Medicamen Organics Ltd IPO?

    'Pre-apply' for Medicamen Organics Ltd IPO indicates your interest in the IPO before it opens for subscription. This ensures quick application when the IPO goes live.

  • When will my Medicamen Organics Ltd IPO order be placed?

    Your Medicamen Organics Ltd IPO order will be placed on 21 Jun 2024.

  • What are the open and close dates of the Medicamen Organics Ltd IPO?

    The open and close dates of the Medicamen Organics Ltd IPO are 21 Jun 2024 to 25 Jun 2024.

  • What is the lot size and minimum order quantity of the Medicamen Organics Ltd IPO?

    The lot size and minimum order quantity of the Medicamen Organics Ltd IPO are 4000 and 4000 respectively.

  • What would be the listing gains on the Medicamen Organics Ltd IPO?

    The potential listing gains on the Medicamen Organics Ltd IPO will depend on various market factors and cannot be predicted with certainty.